Barclays Reiterates Equal-Weight Rating on Tandem Diabetes Care, Inc. (TNDM)

Market Context

Tandem Diabetes Care, Inc. operates in the Healthcare sector. The stock currently trades at $16.91 with a market capitalization of $1.4B. The stock has gained 18.3% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tandem Diabetes Care, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Tandem Diabetes Care, Inc.

Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 06, 2026	Barclays	Equal-Weight	N/A
Nov 06, 2026	Wells Fargo	Overweight	N/A
Oct 07, 2026	Barclays	Equal-Weight	N/A
Sep 30, 2026	Citigroup	Neutral	N/A
Sep 24, 2026	Truist Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View TNDM Stock Page